Biohaven Ltd's stock price increased by 19.02%, crossing above the 5-day SMA, reflecting positive investor sentiment.
This surge is attributed to the upcoming presentation by CEO Vlad Coric at the J.P. Morgan Healthcare Conference on January 12, 2026, where he will showcase the company's advancements in biopharmaceuticals. This event is expected to attract significant investor and industry attention, highlighting Biohaven's innovative portfolio in key therapeutic areas such as immunology and neuroscience.
The anticipation surrounding the conference and the potential for future revenue growth from Biohaven's proprietary drug development platforms suggest a positive outlook for the company, despite the inherent risks associated with FDA approvals and market uncertainties.
Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 15.09 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 15.09 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
6 Hold
0 Sell
Moderate Buy
Current: 12.100
Low
9.00
Averages
15.09
High
30.00
Current: 12.100
Low
9.00
Averages
15.09
High
30.00
RBC Capital
Sector Perform -> Outperform
upgrade
$9 -> $22
2026-01-21
Reason
RBC Capital
Price Target
$9 -> $22
AI Analysis
2026-01-21
upgrade
Sector Perform -> Outperform
Reason
RBC Capital upgraded Biohaven to Outperform from Sector Perform with a price target of $22, up from $9. The stock's reward/risk is "more compelling" following Biohaven's recent data, the analyst tells investors in a research note. The firm believes the data "take the worst-case scenario off the table and changes the risk profile of a key upcoming catalyst." In addition, Biohaven's degrader updates highlight the platform's potential in both Graves disease and IgA Nephropathy, contends RBC. The firm says the company's improved financial position and valuation discount relative to the platform's opportunity "creates a compelling setup" into the second half of 2026 catalysts.
Stifel
Paul Matteis
Buy
maintain
2025-12-26
Reason
Stifel
Paul Matteis
Price Target
2025-12-26
maintain
Buy
Reason
Stifel analyst Paul Matteis is reiterating a Buy rating on Xenon Pharmaceuticals (XENE) following Biohaven's (BHVN) Kv7 drug failing in a study in major depression disorder as the firm continues to believe that there's limited evidence suggesting that Biohaven's Kv7 compound BHV-7000 will be as efficacious as XEN1101. The firm, which continues to like Xenon shares heading into a pivotal 2026 with Phase 3 data for '1101 in FOS, keeps a Buy rating on Xenon shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BHVN
Unlock Now
H.C. Wainwright
H.C. Wainwright
Neutral
maintain
$11
2025-12-26
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$11
2025-12-26
maintain
Neutral
Reason
H.C. Wainwright is not surprised by Biohaven's (BHVN) BHV-7000 study failure in major depressive disorder. However, investors have largely been focused on the company's readout in focal onset seizures, the analyst tells investors in a research note. H.C. Wainwright believes the depression failure reinforces its caution headed into the seizures readout. It adds that Biohaven's miss does not meaningfully influence its expectations for Xenon Pharmaceuticals' (XENE) azetukalner Phase 3 study in major depressive disorder. H.C. Wainwright keeps a Neutral rating on Biohaven with an $11 price target.
William Blair
Myles Minter
Market Perform
maintain
2025-12-26
Reason
William Blair
Myles Minter
Price Target
2025-12-26
maintain
Market Perform
Reason
William Blair analyst Myles Minter keeps a Market Perform rating on Biohaven after the company's Phase II study miss for BHV-7000 in major depression disorder. While disappointing, William Blair was cautious into the study given difficulties in depression clinical trial execution and placebo creep in trials over recent years, the analyst tells investors in a research note. The firm looks to the pivotal data for BHV-7000 in focal onset epilepsy in first half of 2026 as a key data point to determine if the extended-release formulation of the drug is an active formulation. It sees limited negative readthrough to Xenon Pharmaceuticals' (XENE) depression study from Biohaven's miss.
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
